Galmed Pharma (GLMD): Cutting PT On Dilution - HC Wainwright - StreetInsider.com

Galmed Pharma (GLMD): Cutting PT On Dilution - HC Wainwright
StreetInsider.com
H.C. Wainwright analyst, Ed Arce, reiterated his Buy rating on shares of Galmed Pharmaceuticals (NASDAQ: GLMD) noting multiple upcoming catalysts but cut his price target to $12 due to the 9% share dilution in 4Q16. On January 9, Galmed announced ...